Journal of Neurochemistry · 2000 · 86 citations · 43 references
MedicineNeurosciencePharmacologyNeurochemistryNeuropharmacologyPharmacodynamicsDopaminergic PharmacologyDopaminergic SignalingMonoamine NeurochemistryNeurochemical PharmacologyNeuromodulationNeuroprotectionDopaminergic ModulationDopaminergic NeuronsDopaminergic PathwaysDopaminergic System EffectsMicrodialysis MeasurementNigrostriatal Dopamine PathwayNigrostriatal Dopamine SystemParkinson’s Disease Pharmacotherapy
The influence of L-DOPA and reserpine on extracellular dopamine (DA) levels in the striatum of intact and dopaminergic denervated rats was studied using the brain microdialysis technique. In intact rats, reserpine (5 mg/kg s.c.) reduced extracellular DA levels to 4% of basal values. L-DOPA (50 mg/kg i.p.) had no effect on extracellular DA levels in reserpine-pretreated rats. In rats with 6-hydroxydopamine-induced lesion of the nigrostriatal dopaminergic system, basal levels of extracellular DA were low but markedly increased by L-DOPA (50 mg/kg i.p.). In 6-hydroxydopamine-lesioned rats, pretreatment with reserpine (5 mg/kg s.c.) diminished L-DOPA (50 mg/kg i.p.)-induced increases in extracellular DA levels to 16% of those obtained in denervated animals not pretreated with reserpine (p<0.01). These results suggest that in the intact striatum, extracellular DA stems mainly from vesicular storage sites and that in the striatum with dopaminergic denervation, a large part of the L-DOPA-derived extracellular DA is also derived from a vesicular pool that is released by an exocytosis mechanism.
43
Biochemical pathophysiology of Parkinson's disease.
O Hornykiewicz, Stephen J. Kish · PubMed · 1987 · 852 citations
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
C. D. Marsden, J. D. Parkes · The Lancet · 1977 · 590 citations
Medicine, Neurology, Pharmacotherapy +10